par Procter, Marion;Suter, Thomas;de Azambuja, Evandro
;Dafni, U;van Dooren, Veerle;Muehlbauer, Susanne;Climent, Miguel Angel;Rechberger, Ernst;Liu, Walter Tsang-Wu;Toi, Masakazu;Coombes, Raoul Charles;Dodwell, David;Pagani, Olivia;Madrid, Jorge;Hall, Marcia;Chen, Shin-Cheh;Focan, Christian;Muscholl, Michael;van Veldhuisen, Dirk J;Piccart-Gebhart, Martine 
Référence Journal of clinical oncology, 28, 21, page (3422-3428)
Publication Publié, 2010-07


Référence Journal of clinical oncology, 28, 21, page (3422-3428)
Publication Publié, 2010-07
Article révisé par les pairs
Titre: |
|
Auteur: | Procter, Marion; Suter, Thomas; de Azambuja, Evandro; Dafni, U; van Dooren, Veerle; Muehlbauer, Susanne; Climent, Miguel Angel; Rechberger, Ernst; Liu, Walter Tsang-Wu; Toi, Masakazu; Coombes, Raoul Charles; Dodwell, David; Pagani, Olivia; Madrid, Jorge; Hall, Marcia; Chen, Shin-Cheh; Focan, Christian; Muscholl, Michael; van Veldhuisen, Dirk J; Piccart-Gebhart, Martine |
Informations sur la publication: | Journal of clinical oncology, 28, 21, page (3422-3428) |
Statut de publication: | Publié, 2010-07 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Antibodies, Monoclonal -- adverse effects |
Antibodies, Monoclonal, Humanized | |
Antineoplastic Agents -- adverse effects | |
Breast Neoplasms -- drug therapy | |
Female | |
Heart Failure -- chemically induced | |
Humans | |
Receptor, erbB-2 -- analysis | |
Ventricular Function, Left -- drug effects | |
Note générale: | Clinical Trial, Phase III |
Journal Article | |
Multicenter Study | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2009.26.0463 | |
info:pii/JCO.2009.26.0463 | |
info:pmid/20530280 |